Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The study aimed to investigate the effects of Sry-like high mobility group box 15 (
SOX15
) on proliferation and migration of
endometrial cancer
(EC) cells. Immunohistochemistry (IHC) was applied to determine the expression of
SOX15
in EC tissues and adjacent tissues. We used cell transfection method to construct the HEC-1-A and Ishikawa cell lines with stable overexpression and low expression
SOX15
Reverse-transcription quantitative real-time PCR (RT-qPCR) and Western blot were performed to examine expression of
SOX15
mRNA and
SOX15
protein, respectively. By conducting a series of cell proliferation assay and migration assay, we analyzed the influence of
SOX15
overexpression or low expression on EC cell proliferation and migration. The expression of
SOX15
mRNA and protein in EC tissues was significantly lower than that in adjacent tissues. After lentivirus-transfecting
SOX15
, the expression level of
SOX15
mRNA and protein was significantly increased in cells of
SOX15
group, and decreased in sh-
SOX15
group. Overexpression of
SOX15
could suppress cell proliferation, while down-regulation of
SOX15
increased cell proliferation. Flow cytometry results indicated that overexpression of
SOX15
induced the ratio of cell-cycle arrest in G
1
stage. In addition, Transwell migration assay results showed that
SOX15
overexpression significantly inhibited cell migration, and also down-regulation of
SOX15
promoted the migration. As a whole,
SOX15
could regulate the proliferation and migration of EC cells and up- regulation of
SOX15
could be valuable for EC treatment.
...
PMID:
SOX15
regulates proliferation and migration of endometrial cancer cells. 2882 64
We previously reported that SOX4 is overexpressed in
endometrial cancer
and that it partially contributes to hypermethylation of miR-129-2 and miR-203. The current study seeks to identify methylation and expression levels of the SOX gene family in endometrial carcinomas. Methylation levels of the 16 SOX gene family members were measured by combining bisulfite restriction analysis (COBRA), MassARRAY, and pyrosequencing assays of cell lines and
endometrial cancer
samples. Gene expression was determined by RT-qPCR. The methylation level of the SOX11 locus was correlated with clinicopathologic factors in primary endometrial tumors and in TCGA endometrial cohort. It was also examined in DNA of serum and endometrial specimens from a longitudinal cohort of early stage
endometrial cancer
patients. COBRA assays indicated that hypermethylation of SOX1, SOX2, SOX11, SOX14,
SOX15
, SOX17, and SOX18 was present in
endometrial cancer
cell lines and not in the normal control. SOX11 expression was reactivated only by a DNA methylation inhibitor. Moreover, aberrant DNA methylation of SOX11 was detected in the majority of endometrioid endometrial carcinomas (n=114) and none of the 22 adjacent normal endometrial samples (P<0.0001). The methylation status of SOX11 associated significantly with microsatellite instability and MLH1 methylation in endometrial tumors (P<0.0001), and this finding was validated in TCGA endometrial cohort. Furthermore, SOX11 was not hypermethylated in serum DNA from early stage
endometrial cancer
patients. This study found that hypermethylation of SOX11 is common in endometrial carcinomas and strongly associates with microsatellite instability and MLH1 methylation.
...
PMID:SOX11 hypermethylation as a tumor biomarker in endometrial cancer. 3093 61
